Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.

Cell reports. Medicine - 21 Apr 2020

Iepsen Eva W, Have Christian T, Veedfald Simon, Madsbad Sten, Holst Jens J, Grarup Niels, Pedersen Oluf, Brandslund Ivan, Holm Jens-Christian, Hansen Torben, Torekov Signe S

Abstract excerpt

Individuals with obesity due to pathogenic heterozygous melanocortin 4 receptor (MC4R) mutations can be treated efficiently with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) liraglutide. Here, we report the effect of 16 weeks of liraglutide 3 mg/day treatment in a woman with morbid obesity and type 2 diabetes (T2D) due to homozygous pathogenic MC4R mutation. The body weight loss was 9.7 kg, similar to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Denmark

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Homozygote

Share to Mutation

Share to Obesity, Morbid

Share to Receptor, Melanocortin, Type 4

Share to Weight Loss

Source

Open in PubMed Open full text

Identifiers

PMID: 33205056
DOI: 10.1016/j.xcrm.2020.100006
PMCID: PMC7659505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report.PMID 33205056Read ↗

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.Semantic proximity Read ↗

Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor.Semantic proximity Read ↗

Exploring the off-Label use of liraglutide in the treatment of obesity: a reviewSemantic proximity Read ↗

Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiencySemantic proximity Read ↗

Monogenic Obesity; Using Drugs to Bypass the Problem.Semantic proximity Read ↗

Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency.Semantic proximity Read ↗

Short-term Weight Trajectory of Severely Obese Individuals With and Without Pathogenic Satiety-Regulation Melanocortin 3/4 Receptor (MC3/4R) Mutations From a Multi-ethnic Asian Large Bariatric Surgery Program.Semantic proximity Read ↗

RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.Semantic proximity Read ↗

A Novel homozygous missense mutation of melanocortin-4 receptor (MC4R) in a Japanese woman with severe obesity.Semantic proximity Read ↗

Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.Semantic proximity Read ↗

Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity.Semantic proximity Read ↗

Weight loss after Roux-en-Y gastric bypass in obese patients heterozygous for MC4R mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.